Recurring thrombocytopenia associated with structured treatment interruption in patients with human immunodeficiency virus infection.
In a structured treatment interruption (STI) trial, 3 of 23 patients in a CD4 cell count-guided treatment arm developed recurring thrombocytopenia associated with the interruption of antiretroviral therapy. All 3 patients had slightly low or normal platelet counts before initiating antiretroviral therapy. STI may play a role in inducing thrombocytopenia in patients with human immunodeficiency virus infection.
Ananworanich
Jintanat
J
Human Immunodeficiency Virus Netherlands Australia Thailand Research Collaboration and Thai Red Cross Acquired Immunodeficiency Syndrome Research Center, Pathumwan, Bangkok, Thailand 10330. jintanat.a@chula.ac.th
Phanuphak
Nittaya
N
Nuesch
Reto
R
Apateerapong
Wichitra
W
Rojnuckarin
Ponlapat
P
Ubolyam
Sasiwimol
S
Phanuphak
Praphan
P
Ruxrungtham
Kiat
K
D000328:Adult; D018791:CD4 Lymphocyte Count; D004334:Drug Administration Schedule; D015658:HIV Infections / Q000188:drug therapy* / Q000201:enzymology; D017320:HIV Protease Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D010976:Platelet Count; D016032:Randomized Controlled Trials as Topic; D012008:Recurrence; D018894:Reverse Transcriptase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D013921:Thrombocytopenia / Q000209:etiology*
D017320:HIV Protease Inhibitors; D018894:Reverse Transcriptase Inhibitors